Andersons pediatric cardiology 1669

85.CoppiniR,FerrantiniC,YaoL,etal.Late
sodiumcurrentinhibitionreverses
electromechanicaldysfunctioninhuman
hypertrophiccardiomyopathy.Circulation.
2013;127(5):575–584.
86.GeorgakopoulosD,ChristeME,GiewatM,etal.
Thepathogenesisoffamilialhypertrophic
cardiomyopathy:earlyandevolvingeffectsfrom
analpha-cardiacmyosinheavychainmissense
mutation.NatMed.1999;5(3):327–330.
87.AlvesML,GaffinRD,WolskaBM.Rescueof
familialcardiomyopathiesbymodificationsat
thelevelofsarcomereandca2+fluxes.JMol
CellCardiol.2010;48(5):834–842.
88.FatkinD,McConnellBK,MuddJO,etal.An
abnormalca(2+)responseinmutantsarcomere
protein-mediatedfamilialhypertrophic
cardiomyopathy.JClinInvest.
2000;106(11):1351–1359.
89.CoppiniR,MazzoniL,FerrantiniC,etal.
Ranolazinepreventsphenotypedevelopmentin
amousemodelofhypertrophiccardiomyopathy.
CircHeartFail.2017;10(3).
90.KohlerJ,WinklerG,SchulteI,etal.Mutationof
themyosinconverterdomainalterscross-bridge
elasticity.ProcNatlAcadSciUSA.
2002;99(6):3557–3562.


91.SpudichJA.Hypertrophicanddilated
cardiomyopathy:fourdecadesofbasicresearch

onmuscleleadtopotentialtherapeutic
approachestothesedevastatinggeneticdiseases.
BiophysJ.2014;106(6):1236–1249.
92.SpudichJA.Themyosinmesaandapossible
unifyinghypothesisforthemolecularbasisof
humanhypertrophiccardiomyopathy.Biochem
SocTrans.2015;43(1):64–72.
93.CrilleyJG,BoehmEA,BlairE,etal.
Hypertrophiccardiomyopathyduetosarcomeric
genemutationsischaracterizedbyimpaired
energymetabolismirrespectiveofthedegreeof
hypertrophy.JAmCollCardiol.
2003;41(10):1776–1782.
94.AbozguiaK,ElliottP,McKennaW,etal.
Metabolicmodulatorperhexilinecorrectsenergy
deficiencyandimprovesexercisecapacityin
symptomatichypertrophiccardiomyopathy.
Circulation.2010;122(16):1562–1569.
95.GreenEM,WakimotoH,AndersonRL,etal.A
small-moleculeinhibitorofsarcomere
contractilitysuppresseshypertrophic
cardiomyopathyinmice.Science.
2016;351(6273):617–621.
96.BeadleRM,WilliamsLK,KuehlM,etal.
Improvementincardiacenergeticsby


perhexilineinheartfailureduetodilated
cardiomyopathy.JACCHeartFail.
2015;3(3):202–211.

97.HoCY,LakdawalaNK,CirinoAL,etal.
Diltiazemtreatmentforpre-clinicalhypertrophic
cardiomyopathysarcomeremutationcarriers:a
pilotrandomizedtrialtomodifydisease
expression.JACCHeartFail.2015;3(2):180–
188.
98.OlivottoI,HellawellJL,Farzaneh-FarR,etal.
Novelapproachtargetingthecomplex
pathophysiologyofhypertrophic
cardiomyopathy:theimpactoflatesodium
currentinhibitiononexercisecapacityin
subjectswithsymptomatichypertrophic
cardiomyopathy(LIBERTY-HCM)trial.Circ
HeartFail.2016;9(3):e002764.
99.HoCY,McMurrayJJV,CirinoAL,etal.The
designofthevalsartanforattenuatingdisease
evolutioninearlysarcomerichypertrophic
cardiomyopathy(VANISH)trial.AmHeartJ.
2017;187:145–155.
100.AokiY,NiihoriT,KawameH,etal.Germline
mutationsinHRASproto-oncogenecause
costellosyndrome.NatGenet.
2005;37(10):1038–1040.
101.BurchM,SharlandM,ShinebourneE,etal.